Novartis' President of Biomedical Research, Fiona Marshall, outlines a research strategy that treats aging as the principal upstream driver of cardiovascular, neurodegenerative, and oncologic disease, targeting mitochondrial dysfunction, declining DNA repair, and extracellular matrix alterations. The stated ambition shifts from decelerating decline to restoring healthy tissue. Marshall also proposes stratifying patients by 'aging endotypes' — dominant biological drivers such as inflammation, metabolic dysfunction, or impaired DNA repair — identified through proteomic signatures.
Key Points
- Novartis targets mitochondrial decline, DNA repair loss, matrix alterations
- Aging endotypes would match therapies to dominant individual drivers
- Inflammation data from CANTOS supports inflammaging as tractable target
Longevity Analysis
Stratification by dominant aging driver addresses a persistent weakness in geroscience trials: heterogeneous populations diluting real effects. One person's decline may be led by chronic immune activation, another's by failing energy production at the mitochondrial level, another's by accumulated genomic damage — and the correct intervention differs accordingly. Reading those signatures accurately determines whether a therapeutic restores tissue or merely slows its loss, and the regenerative framing raises the ceiling on what intervention can achieve beyond maintenance.
Original published by Longevity.Technology, by Phil Newman.